The Role of Cetuximab in Pre-Treated Refractory Patients with Metastatic Colorectal Cancer: Outcome Study in Clinical Practice

We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with iri...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2008-06, Vol.20 (3), p.374-379
Main Authors: Lelli, G., Cataldo, S., Carandina, I., Urbini, B., Bonetti, F., Marzola, M., Biasco, G., Pantaleo, M.A., Brandes, A., Calandri, C., Ravaioli, E., Nanni, O., Boni, C., Banzi, C., Negri, F., Panetta, A., Di Fabio, F., Turci, D.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
appropriate prescriptions
Biological and medical sciences
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Cetuximab
Clinical outcome
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - mortality
Disease Progression
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
multicenter study
Multivariate Analysis
palliative treatment
Pharmacology. Drug treatments
Retrospective Studies
retrospective study
Skin - drug effects
Skin Diseases - chemically induced
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
targeted therapies
Tumors
Weight Loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2008.20.3.374